RHY ASX · Health Care

RHYTHM Biosciences Ltd

Announcements, last 12 months: 99
Price sensitive, last 12 months: 18
Followed on InvestorPA: Low (Outside the 20% most-followed companies on InvestorPA)

Latest announcements

Released	Headline	Actions
7 Oct 2026, 9:10 AM	ColoSTAT Economic Study - Australian Public Health Savings Price sensitive	AI summary
30 Sep 2026, 5:18 PM	Final Director's Interest Notice - Gavin Fox-Smith
29 Sep 2026, 4:52 PM	FY26 Appendix 4G and Corporate Governance Statement
29 Sep 2026, 4:51 PM	FY26 Annual Report
29 Sep 2026, 12:09 PM	AGM date and closing date for director nominations
29 Sep 2026, 8:11 AM	Board Changes
22 Sep 2026, 8:24 AM	Initial ColoSTAT Assessment in UK opens new market access Price sensitive	AI summary
28 Aug 2026, 3:07 PM	Initial Director's Interest Notice - Carl Stubbings
28 Aug 2026, 3:06 PM	Initial Director's Interest Notice - Maureen Baker
27 Aug 2026, 5:04 PM	FY26 Appendix 4E & Audited Financial Report Price sensitive	AI summary

Sign in to see all RHY announcements.

Guidance history

27 Aug 2026	FY26 revenue: $85,339; Loss after tax: $5.93 million; Cash at 30 June: $3.36 million
30 Jul 2026	Expect cash reserves to fund operations through 4Q FY27
30 Apr 2026	The company expects to increase ColoSTAT® test volumes through the 4Cyte network and ColoSTAT® Access Program, progress the NHS England laboratory ColoSTAT® analytical evaluation, expand geneType domestic and international commercial partnerships, and advance strategic pathways for ColoSTAT® commercial expansion in Q4 FY26.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow RHY to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.